Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Pancreatic Neoplasms 40 Neoplasms 5 Colorectal Neoplasms 5 Neoplasm Metastasis 3 Resectable Pancreatic Cancer 2 Rectal Neoplasms 2 Carcinoma, Hepatocellular 2 Adenocarcinoma 2 Urachal cancer 1 Stomach Neoplasms 1 Pancreatic Ductal Adenocarcinoma (PDAC) 1 Pancreatic Cancer Metastatic 1 Pancreatic Adenocarcinoma 1 Neoplasms, Basal Cell 1 Locally Advanced Pancreatic Adenocarcinoma 1 Localized Pancreatic Adenocarcinoma 1 Gastrointestinal Neoplasms 1 Gastroesophageal Adenocarcinoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Cancer Metastatic 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Islet Cell 1 Borderline Resectable Pancreatic Cancer 1 Biliary Tract Neoplasms 1 Ampullary Adenocarcinoma 1

Interventions

folfirinox 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Ampullary Adenocarcinoma × folfirinox × Clear all

NCT06068023 2023-10-05

ADAPTA

Fondazione Poliambulanza Istituto Ospedaliero

Ampullary Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡